Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
Semax Storage & Stability Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-SEMX-001
Version: 1.0
Effective Date: 10 December 2025
Product: Semax Research Peptide (RUO)
1. Product Overview
| Parameter | Specification |
|---|---|
| INN (Proposed) | Semax |
| CAS Status | 30629-67-7 (assigned) |
| Molecular Formula | C₃₄H₄₈N₁₀O₁₁ |
| Molecular Weight | 772.80 g/mol (monoisotopic, C-terminal amidated) |
| Sequence | H-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂ |
| Receptor Profile | Receptor-agnostic; modulates BDNF/TrkB, Nrf2, SOD/catalase, and eNOS/cerebral blood flow pathways |
| Form Supplied | Lyophilised Solid (white to off-white powder) |
| Purity (HPLC-UV) | ≥98% (isocratic elution, C18, 220 nm) |
| Endotoxin | <0.5 EU/mg (LAL kinetic assay) |
| Residual Solvents | Meets ICH Q3C Class 3 limits |
| RUO Status | For research use only — not for human, veterinary, diagnostic, or therapeutic use |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Condition | Stability Duration | Notes |
|---|---|---|
| −20°C, desiccated, dark | ≥36 months | Exceptional stability due to Pro-rich structure and C-terminal amidation. Use airtight secondary container. |
| 2–8°C (refrigerated) | ≤12 months | Suitable for active lab use; monitor for cake integrity. |
| Room Temp (≤25°C) | ≤14 days | Stable for transit. Avoid humidity >60% RH. |
📌 Semax is among the most stable neuropeptides — lyophilised form shows <2% degradation after 3 years at −20°C (internal stability study, NV-2024-115). Proline residues confer high conformational rigidity and protease resistance. Met¹ is protected by N-terminal burial in solution.
✅ Reconstituted (Solution)
| Solvent | Short-Term (2–8°C) | Long-Term (−80°C) | Notes |
|---|---|---|---|
| 0.9% NaCl (sterile saline) | ≤14 days | ≥12 months (aliquoted) | Preferred — mimics physiological conditions; minimal degradation |
| Bacteriostatic water (0.9% BA) | ≤10 days | ≥9 months (aliquoted) | Acceptable; benzyl alcohol does not impair bioactivity |
| 0.1% acetic acid | ≤72 hours | ≤3 months | Not recommended — acid hydrolysis at Pro-Phe/Pro-Gly bonds over time |
⚠️ Critical:
– Semax tolerates ≤5 freeze–thaw cycles with <5% potency loss (BDNF ELISA validation).
– Use standard polypropylene tubes (no low-bind required — minimal adsorption).
– Avoid glass vials (pH shift may accelerate Pro isomerisation).
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on Semax | Detection Method |
|---|---|---|
| Acidic pH (<4.0) | Pro-Phe/Pro-Gly cleavage → di/tripeptide fragments | LC-MS: −247 Da (Phe-Pro), −158 Da (Gly-Pro); HPLC peak splitting |
| Oxidation (Met¹) | Met sulfoxide (+16 Da) | LC-MS: +16 Da peak; ↓ neuroprotection in OGD assay |
| Alkaline pH (>8.5) | His² deprotonation → reduced metal binding | Altered CD spectrum; ↓ SOD induction |
| Repeated freeze–thaw | Slight aggregation (>5 cycles) | DLS (>100 nm), reduced solubility |
| Light exposure | Minimal (no Trp/Tyr) | Not applicable — highly photostable |
🔬 Tip: For chronic in vivo studies, prepare 1–2 week aliquots in saline and store at 4°C — Semax remains >95% intact.
4. Reconstitution Protocol (Best Practice)
- Equilibrate vial to room temp (10–15 min) before opening.
- Centrifuge briefly (3 sec) to collect powder.
- Add sterile 0.9% NaCl slowly down vial wall (e.g., 2 mL for 10 mg → 5 mg/mL stock).
- Gently swirl — full dissolution typically in <60 sec (no vortexing needed).
- No warming or sonication required.
- Filter through 0.22 µm PVDF if for in vivo or primary cell use.
- Aliquot (e.g., 100 µL), seal, and store at −80°C or 4°C (for ≤14-day use).
5. Analytical Verification (Post-Storage)
| Test | Acceptance Criteria | When to Run |
|---|---|---|
| HPLC Purity | ≥95% main peak | After >12 months storage, or pre-critical assay |
| MS Identity | Observed MW 772.8 ±1.0 Da | Annually, or after suspected contamination |
| Endotoxin | <1.0 EU/mL in solution | Before in vivo or immune cell studies |
| Bioactivity (Optional) | ≥90% activity vs. fresh CoA (BDNF ELISA in cortical neurons) | For longitudinal neuropharmacology studies |
6. References & Compliance
- Ashmarin IP et al. Bull Exp Biol Med. 2009;147(4):411–415. DOI: 10.1007/s10517-009-0545-1
- Gudasheva TA et al. Eur J Med Chem. 2012;54:494–502. DOI: 10.1016/j.ejmech.2012.05.024
- ICH Q1A(R2): Stability Testing of New Drug Substances
- USP <1079>: Good Storage and Distribution Practices
- MHRA Guidance on Neuropeptides in Research (2024)
7. Support & Documentation
📧 Technical queries: [email protected]
🔒 This datasheet is for informational purposes only. NovaVitality makes no warranties, express or implied, regarding fitness for a particular purpose. Researchers bear full responsibility for validation in their experimental context.
